Zoetis, Inc. Class A (ZTS)

Zoetis's stock price has experienced a significant decline over the past six months, influenced by the company's Q1 2026 earnings report, which missed expectations. The company lowered its full-year 2026 guidance, citing a more challenging operating environment, particularly softer demand for companion animal products in the U.S. The company has faced pressure from generic competition, as seen with its respiratory drug Draxxin. A notable event impacting the stock was the controversy surrounding Librela, an osteoarthritis treatment for dogs, which faced backlash due to reported side effects. In a positive development, Zoetis agreed to acquire Neogen's animal genomics business for $160 million in March 2026.

While explicit demand seasonality for Zoetis's products and services is not detailed, there are indications of demand fluctuations. The company has recently experienced softer end-market demand for companion animal products in the U.S., attributed to increased price sensitivity among pet owners and a decline in veterinary visits. Despite this, the overall demand for veterinary care is noted as strong. The international companion animal business has shown growth comparable to the U.S. segment, helping to offset some of the domestic softness. Zoetis anticipates future growth driven by rising demand for animal proteins in emerging markets and increased spending on pets by younger demographics.

Zoetis, Inc. is a global animal health company focused on discovering, developing, manufacturing, and commercializing medicines, vaccines, diagnostics, and technologies for companion animals and livestock. The company's business focuses on predicting, preventing, detecting, and treating animal illnesses, with major product categories including anti-infectives, vaccines, parasiticides, and diagnostic products. Key products include monoclonal antibody therapies for osteoarthritis pain and Simparica Trio for parasite prevention. Approximately 70% of the company's revenue is generated from companion animal products, with the remaining 30% from livestock products.

Headquartered in Parsippany, New Jersey, Zoetis markets its products in over 100 countries and maintains a local presence in approximately 70 countries. Its operations span nearly 45 countries across North America, Europe, Africa, Asia, Australia, and South America, with international operations contributing 50% of its total revenue. Zoetis's manufacturing network comprises 28 sites across 11 countries, with 60% of its global manufacturing taking place at its nine U.S. sites located in seven states. Significant subsidiaries are primarily concentrated in Europe and North America, accounting for 63.03% of its material entities. Research and development efforts are led from its global R&D headquarters in Kalamazoo, Michigan, supported by teams in various U.S. states, Europe, Australia, and emerging markets like Brazil, India, and China.

Zoetis generally maintains a strong brand and reputation, holding the largest market share in the animal health industry. The company has also been recognized by Forbes. However, the company's brand reputation has been negatively impacted in the past year by the controversy surrounding Librela, its osteoarthritis treatment for dogs, due to safety concerns. Although a class action lawsuit related to Librela was dismissed, the damage to the brand's reputation could affect future sales performance. The European Medicines Agency also confirmed safety concerns regarding Librela in March 2026.

Zoetis's ownership structure includes institutional, retail, and individual investors. Institutional investors hold the majority of outstanding shares, with major shareholders including Vanguard Group Inc and BlackRock, Inc. Insiders hold a small portion of the stock, while public companies and individual investors own around 41.03%. David M. Polen of Polen Capital Management, Terry Smith of Fundsmith, and David Rolfe of Wedgewood Partners are among the top holders by percentage of their portfolios.